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Abstract
Celiac disease (CD) is an immune-mediated systemic 
condition evoked by ingestion of gluten and related 
prolamines in genetically susceptible subjects. The 
disease is featured by a variable combination of clinical 
signs, specific antibodies, HLA-DQ2 and HLA-DQ8 
haplotypes, and enteropathy. Vaccination is the most 
potent intervention for infectious disease prevention. 
Several factors including age, gender, ethnicity, quality 
and quantity of vaccine antigen, doses, and route 
of administration can influence immune response to 
vaccination, although the main cause of variation in 
the responsiveness among vaccine recipients is host 
genetic variability. The HLA system has a fundamental 
role in identifying the antigens introduced into the 
host with the vaccines and in the development of 
specific antibodies, and some HLA phenotypes have 
been associated with a less effective immunological 
response. The available literature indicates that the 
immunological response to vaccines in CD children does 
not differ markedly from that of general population and 
antibody titres are high enough to provide long-term 
protection, except for hepatitis B virus vaccine. In this 
article, we review and discuss the scarce literature in 
this field in order to provide clinical practice guidelines 
to achieve the most efficient monitoring of the response 
to vaccines in pediatric CD patients.
Key words: Celiac disease; Children; Infection; Vaccines; 
Hepatitis B vaccine; HLA; Gluten free diet
© The Author(s) 2017. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: The available literature indicates that the 
immunological response to vaccines in children with 
celiac disease (CD) does not differ markedly from that 
of general population and antibody titres are high 
enough to provide long-term protection, except for 
hepatitis B virus (HBV) vaccine. Because the majority 
of persons with CD has the HLA-DQ2 haplotype, it 
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has been hypothesized that such genetic profile could 
have an important part in predisposing CD subjects to 
a less degree of immunity following HBV vaccination. 
New vaccination strategies have been proposed to give 
protection to all of these CD patients. 
Anania C, Olivero F, Spagnolo A, Chiesa C, Pacifico L. Immune 
response to vaccines in children with celiac disease. World J 
Gastroenterol 2017; 23(18): 3205-3213  Available from: URL: 
http://www.wjgnet.com/1007-9327/full/v23/i18/3205.htm  DOI: 
http://dx.doi.org/10.3748/wjg.v23.i18.3205
INTRODUCTION
Celiac disease (CD) is an immune-mediated systemic 
condition evoked by ingestion of gluten and related 
prolamines in genetically susceptible subjects. The 
disease is featured by a variable combination of clinical 
signs and symptoms, specific antibodies, HLA-DQ2 
and HLA-DQ8 haplotypes, and enteropathy. Genetic, 
immunological and environmental factors therefore 
appear to be accountable for the disorder. CD is 
strongly associated with HLA-DQ2 and HLA-DQ8. HLA-
DQ2 is found in 90% to 95% of CD individuals, HLA-
DQ8 haplotype in 5%, and at least one of the two DQ2 
alleles in 5% of them[1,2].
Vaccines have been, and continue to be, among 
the greatest public health achievement in history, 
and they are the most powerful measure for the 
prevention of infectious diseases[3]. They have lowered 
both morbidity and mortality from severe global 
infections such as diphtheria, pertussis, tetanus, 
measles, mumps, rubella, hepatitis B and others[4]. 
Several factors such as age, gender, ethnicity, quality 
and quantity of vaccine antigen, doses, and route 
of administration[5], can influence immune response 
to vaccine, although the main cause of variation in 
the responsiveness among vaccine recipients is host 
genetic variation[6]. Single nucleotide polymorphisms 
(SNPs) in human leukocyte antigen (HLA) class Ⅰ and 
Ⅱ, cytokine and their receptors, and innate immunity 
(i.e., toll-like receptor) genes have been hypothesized 
as responsible for the variability among individuals in 
protective immunity induced by vaccines, including 
neutralizing antibodies[7]. In particular, the HLA system 
has a fundamental role in identifying the antigens 
introduced into the host with the vaccines and in 
the development of specific antibodies[8,9] and some 
HLA phenotypes have been associated with a less 
effective immunological response[10]. The available 
literature indicates that the immunological response to 
vaccines in children with CD does not differ markedly 
from that of general population and antibodies titres 
are high enough to provide long-term protection, 
except for hepatitis B virus (HBV)[11-24]. Although the 
mechanism for HBV vaccination failure in subjects with 
CD is unknown, a few hypotheses have been made. 
There has been advocated that HLA genotype DQ2 
may predispose CD subjects to a lesser degree of 
immunization to recombinant HBV vaccine[11,25-27]. HLA-
DQ2 haplotype may be responsible for lack of induction 
of the Th2 response that is necessary for B cell 
differentiation and formation of memory B cells. Other 
authors have suggested that the response to HBV 
vaccination in individuals affected by CD may depend 
on disease activity and compliance to a gluten free 
diet (GFD)[12,13,15,18]. Indeed, gluten consumption at the 
time of vaccination has been hypothesized as a cause 
of failure of immunity. Gluten may be implicated since 
both HBV surface antigen (HbsAg) protein fractions 
and gliadin peptides fasten to HLA-DQ2 particles and 
activate proliferation of T lymphocytes[12]. Contention 
between the proteins might lead to impaired antibody 
synthesis. In this article, we review and discuss the 
scarce literature on this field in order to provide 
clinical practice guidelines to achieve the most efficient 
monitoring of the response to vaccines in pediatric CD 
patients.
CELIAC DISEASE AND THE RISK OF 
INFECTIONS
Several respiratory infections have been associated 
with CD in adults, such as invasive pneumococcal 
disease (i.e., pneumonia)[28-30], sepsis[31] , incident 
tuberculosis[32], and death resulting from tuberculosis[33]. 
In addition, children with CD have a higher risk of 
influenza infection and secondary hospital admission[21]. 
The increased infection risk in CD patients is probably 
due to several factors. Malnutrition or increased 
intestinal permeability associated with CD could be one 
of them. Defective nutritional status, that is frequent 
both in CD and in patients with subclinical disease as 
well as following the start of GFD[34], can result in lack 
of folate, vitamin B12, and in poor vitamin D status. 
Deficiency of folate and vitamin B12 are correlated 
with a decrease in immune-competence[35] and a 
higher burden of respiratory infections (including 
influenza)[36,37], while poor vitamin D status[38] may 
result in the impairment of the defense mechanisms 
against respiratory pathogens and predispose to 
respiratory infections such as influenza and tuber-
culosis[39]. CD patients have increased intestinal 
mucosal permeability, but not only[40]: respiratory 
mucosal permeability is also increased[41], and this may 
facilitate the entry of influenza virus. Hyposplenism 
also occurs in CD, although this condition seems to be 
important only in adult cases of CD[42]. 
Thus, it is essential to implement a comprehensive 
vaccination program for CD patients with the available 
vaccines and to evaluate immunological response to 
these vaccines in CD patients.
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RESPONSES TO VACCINATIONS IN 
CHILDREN WITH CELIAC DISEASE
There are few studies on the antibody response to 
vaccines of patients with CD. The majority relate 
to HBV, while very few reports are available on the 
immunological response to other vaccinations.
Some reports imply that celiac patients may 
have a low level of protective antibodies after HBV 
vaccination. The lack of response among CD subjects 
to HBV vaccination is important for public health 
policies because these non-responders may be a 
reservoir for HBV[43]. The published studies on the 
association between CD and HBV vaccination in 
children are presented in Table 1[11-21,24]. In the earliest 
report, involving 26 celiac patients aged 9.2 ± 4.6 
years and 18 age-matched controls, receiving the full 
complement of childhood vaccination (HBV, tetanus, 
rubella, Haemophilus influenzae type b), Park et al[11] 
showed that a significantly greater percentage of 
children with CD did not respond to HBV vaccination 
in comparison with controls (53.9% vs 11.1%, P 
< 0.05). However, all of the children responded to 
other vaccinations. These results led the authors to 
consider the importance of HLA haplotypes in the 
development of immunity to HBV vaccine. Nemes et 
al[12] evaluated HBV vaccine response in CD children 
in relation to disease activity, assessed by measuring 
serum antibody concentrations to transglutaminase, 
and dietary gluten in the failure to reach protective 
antibody titers. The authors studied 128 biopsy-
proven CD children and adolescents and 113 age-
matched controls: 22 patients with CD on GFD were 
prospectively given a recombinant HBV vaccine, while 
the remaining 106 CD patients received a recombinant 
HBV vaccine which was not related to the diagnosis 
of CD or compliance to GFD. They found that the 
rate of seroconversion for anti-HBs was 95.5% 
(95%CI: 78.25%-99.2%) in the patients prospectively 
immunized. However, for the other patients the 
response rate was 50.9% and was related to gluten 
consumption (youths on gluten-containing diet, 25.9%; 
patients non-compliant to GFD, 44.4%; patients on 
strict GFD, 61.4%). These results would suggest the 
importance of disease activity in vaccination failure 
rather than specific HLA alleles[12]. Subsequently, 
Ertem et al[13], evaluated serologically the anti-HBs 
status of 63 biopsy-proved CD patients on a strict GFD 
and 54 healthy children. CD youths with negative anti-
HBs antibodies at baseline were reevaluated after 
full vaccination. The authors demonstrated that the 
seroconversion rate to HBV vaccine in CD patients 
was 96.9%, the same as that observed in the healthy 
population. It was concluded that GFD and compliance 
to diet, rather than the specific HLA alleles may 
increase the immune response to HBV vaccination 
in CD patients[13]. Balamtekın et al[14] compared 
the rates of seroconversion to HBV vaccine in the 
first year of life, utilizing two different immunization 
schedules. The entire study population consisted of 64 
CD children (group 1 who received HBV vaccination 
at birth, at 2 mo and at 9-12 mo of life and group 
2, at birth, 1 mo and 6 mo of life), and 49 healthy 
controls. The response rate to HBV vaccination as well 
as anti-HBs levels in CD children who completed the 
HBV vaccination were significantly lower than that of 
healthy controls, whereas no statistically significant 
difference was observed between the two different 
HBV vaccination schedules[14]. Similarly, Ertekin et 
al[15] evaluated the response to HBV vaccination in 
youths affected by CD compared to healthy children 
and examined the association between the patients’ 
responses, the clinical signs of the disease, and 
compliance to GFD. They evaluated the production of 
specific anti-HBs surface antigen antibodies in 52 CD 
children and 20 controls matched for age and gender 
who received standard HBV vaccination. The authors 
found that 32 (61%) of CD patients had positive anti-
HBs titers, while 18 (90%) of control subjects had 
positive anti-HBs titers. Among youths affected by CD, 
they also showed statistically significant differences 
between responders and non-responders with respect 
to clinical signs of the disease, and compliance to GFD 
(P < 0.05). Thus, they concluded that, in children with 
CD, the immune response to HBV vaccination may be 
improved by compliance to GFD[15]. Leonardi et al[16] in 
a retrospective report confirmed that fewer CD patients 
respond to HBV vaccination than healthy subjects. 
Among 60 CD patients, they found that 30 (50%) 
were non-responders to HBV vaccination while 7 of 
60 controls (11.6%) were non-responders. They also 
demonstrated that a significantly greater proportion 
of non-responders were adolescents older than 14 
years, and concluded that very early diagnosis of CD 
increases the response rate to HBV vaccination. A short 
period of exposure to gluten appears, therefore, to 
have a favorable effect on the antibody memory[16]. In 
a subsequent retrospective study[17], the immunologic 
response against obligatory vaccination (HBV, diphteria 
and tetanus component and Bordetella pertussis) and 
against recommended vaccination (measles virus, 
paramyxoviridae and rubella virus) were compared in 
66 CD patients and 50 healthy children. The authors 
found that the two groups responded similarly to 
obligatory and to recommended vaccines, except for 
HBV vaccine. Moreover, they compared children with 
a diagnosis of CD before and after 18 mo of age, 
and found that an early or a delayed diagnosis does 
not change the immunological response to vaccines, 
with the exception of HBV vaccination. Thus, the 
immunologic response would not appear to be affected 
by the natural history of CD[17]. Urgancy and Kalyoncu[18] 
determined the response rate to hepatitis A (HAV) and 
HBV vaccination, persistence of protection against HAV 
and HBV, and the occurrence of acute HAV or HBV 
infections during a period of follow-up in 30 children 
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Table 1  Immune response to vaccinations in youths with celiac disease 
Ref. Year Country Study design Patients population and 
sample size
Vaccine Non responders HLA 
Park et al[11] 2007 Japan Prospective 26 (mean age ± SD, 9.2 ± 4.6 
yr) untreated CD vs 18 (10.4 
± 3.8) controls
HBV 53.90% NA
 vs 
11.1%, P < 0.05
RUBELLA 0%
vs
0%
TETANUS 3.90%
vs
0%, P = 1.0
HIB 33%
vs
44.4%, P = 0.53
Nemes et 
al[12]
2008 Finland Prospective 22 (mean age, 8.8 yr) 
treated CD prospectively 
immunized;  27 (16.7 yr) 
untreated CD;  79 (16.7 yr) 
treated CD vs 113 (16.1 yr) 
controls
HBV 0.50% Group 1 (22 treated CD):
 74.00% HLA DQ2
38.60%
vs
24.8%, P < 0.001, P < 
0.001, P = 0.102
Group 2 (53/106 treated and 
untreated CD):
51: HLA DQ2
2: HLA DQ8
Leonardi et 
al[16]
2009 Italy Retrospective 60 (mean age, 9.32 yr) 
treated CD vs
60 (10.1 yr) controls
HBV 50% 15/60:
vs 13 HLA-DQ2
11.6%, P < 0.0001 2 HLA-DQ8
Ertem et al[13] 2010 Turkey Retrospective 40 vaccinated (mean age ± 
SD, 12.4 ± 5.4 yr) treated CD 
vs 54 (9.8 ± 3.6 yr) controls
HBV 32.50% 37.5% CD
vs 23.8% controls:
14.8%, P < 0.05 HLA DRB1*03
Prospective 28 prospectively vaccinated 
treated CD
3.60% 21% CD
2.4% controls:
HLA DRB1*07
55% CD
14.6% controls:
HLA DQB1*02
30% CD
47.6% controls:
HLA DQB1*03
Ertekin et 
al[15]
2011 Turkey Retrospective 52 (mean age ± SD, 10.7 ± 
4 yr) CD; vs 20 (10.7 ± 4 yr) 
controls
HBV 38.50% NA
vs 
10%, P < 0.05
Balamtekın 
et al[14]
2011 Turkey Retrospective 64 (mean age ± SD, 4.69 
± 2.31 yr) treated and 
untreated CD vs 49 (mean 
age 5.45 ± 2.92 yr) controls
HBV 21.90% NA
vs 
4.1%, P = 0.001
Urganci and 
Kalyoncu[18]
2013 Turkey Prospective 30 (mean age ± SD, 6.15 ± 4.1 
yr) treated and untreated CD 
vs 50 ( 8.13 ± 1.7 yr) controls
HBV 30% NA
vs
10%, P = 0.03
Leonardi et 
al[17]
2011 Italy Retrospective 66 (mean age ± SD, 8.34 ± 
3.47 yr) CD, vs 50 (7.58 ± 3.51 
yr) controls
HBV 53% NA
vs 
16%, P < 0.0001
POLIO 100%
vs
100%, P = NS
DIPHTHERIA 100%
vs
100%, P = NS
TETANUS 100%
vs
100%, P = NS
MEASLE 72%
vs
82%, P < 0.0001
PAROTITIS 81%
vs
92%, P = NS
RUBELLA 81%
vs
80%, P = NS
PERTUSSIS 54%
vs
54%, P = NS
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affected by CD in comparison with 50 healthy controls 
matched for age, sex, and body mass index[18]. They 
found natural immunity for HAV in 14 (46%) out 30 
CD patients and 15 (30%) of the 50 controls, whereas 
none of the patients and controls showed evidence 
of earlier exposure to HBV. Sixteen of the patients 
and 35 of the controls were vaccinated with HAV; 12 
of the sixteen patients and all the controls (75% vs 
100%) developed anti-HAV antibodies. All of the 30 
youths affected by CD and all of the 50 controls were 
vaccinated with HBV vaccine; 21 (70%) of the patients 
and 45 (90%) of the controls reached seroprotection. 
It was concluded that CD patients achieve a lower 
seroconversion rate to HBV and HAV vaccines than 
controls. Of note, there was a difference in GFD 
compliance between responders and nonresponders, 
though it was not statistically significant. 
Zingone et al[22] evaluated the response to HBV 
vaccine in relation to gluten consumption in three 
groups of patients with CD and in a control group: 
group A, adolescents on gluten-containing diet 
vaccinated at age 12 years in whom CD was diagnosed 
after vaccination; group B, adolescents vaccinated 
when 12-years old who were on GFD at the time 
of vaccination; and group C, patients who received 
HBV vaccine at birth; and group D, healthy subjects. 
An insufficient response to HBV immunization was 
observed in 43.9%, 34.8%, and 58.3% of CD patients 
in group A, B, and C, respectively, vs 8.3% of subjects 
in group D. Thus, the authors suggested that the 
immune response to HBV vaccine is independent 
of gluten exposure and that the human leukocyte 
antigen possibly act as the principal immunological 
determinant of poor responses to HBV vaccine in CD 
patients. Zingone et al[23] also investigated the duration 
of anti-HBs 11 years following primary vaccination 
and immune memory to HBV in adult individuals with 
CD who had been vaccinated when adolescents. They 
showed that the proportion of vaccinated persons with 
antibody titres ≥ 10 mIU/mL was less among CD 
patients than among controls. Finally, in a very recent 
paper Leonardi et al[19] comparing a group of patients 
affected by diabetes mellitus type 1 (DMT1) and CD 
and a group affected by DMT1 without CD (the HLA 
haplotype was similar in both groups), demonstrated 
a higher (though non-significant) proportion of non-
responders, 53.3%, in the DMT1/CD group than in the 
DMT1 group, 38.2%; comparing the DMT1/CD group 
with CD group the authors found a similar percentage 
(53.3% vs 50%) of non-responders and this result 
supports the hypothesis that the efficacy of HBV 
vaccine can be further decreased by gluten, beyond 
the HLA system[19].
The effect of HAV vaccine in children with CD 
was studied by Sari et al[20]. After administration of 
inactivated HAV vaccine intramuscularly in a 2-dose 
schedule at 0 and 6 mo to 33 CD patients and healthy 
controls, the authors found that seroconversion rates 
at 1 mo were 78.8% and 77.4%, respectively; by 
7 mo the rates were 97.0% and 98.4%. Therefore, 
they concluded that in children with CD, HAV vaccine 
produces a good immune response, almost the 
same as healthy controls, and that the routine HAV 
immunization protocol for healthy children may be 
utilized with success in these patients. A prospective 
investigation by Schäppi et al[21] about vaccine 
response in 14 pediatric patients with CD and controls 
matched for age and gender demonstrated that CD 
children achieved protective antibody titers comparable 
with the control group.
Leonardi et 
al[19]
2015 Italy Prospective 30 (mean age, 6 yr) CD/
DMT1 vs 100 (13.6 yr) DMT1 
vs 60 (8.6 yr) CD
HBV 53.3% vs NA
38.2% vs
50%, P > 0.02
Sari et al[20] 2011 Turkey Prospective 33 (mean age ± SD, 8.4 ± 3.6 
yr) CD vs 62 (8.9 ± 3.6 yr) 
controls
HAV 21.2% (after 1 mo) 62.1% CD
3% (after 7 mo) 21.8% controls:
vs HLA-DQ2
22.6% (after 1 mo) 34.8% CD
1.6% (after 7 mo) 9.7% controls:
HLA-DR3
13.6% CD
4.8% controls
HLA-DR7 
Schäppi et 
al[21]
2012 Switzerland Prospective 14 (mean age 12.9 yr) treated 
CD vs 14 (12.9 yr) controls
Influenza 0 50% CD:
A/H1N1/09 vs HLA DQ2
0 heterozygous
50% CD:
HLA DQ2
homozygous
Filippelli et 
al[24]
2016 Italy Prospective 51 CD children at diagnosis HBV 30.60% 23.50%
HLA DQ2
Omozygous
13.70%
HLA DQ2/DQ8
HBV: Hepatitis B virus; CD: Celiac disease; HLA: Human leukocyte antigen; NA: Non available; DMT1: Diabetes mellitus type 1; NS: Not statistically 
significant; HAV: Hepatitis A virus; SD: Standard deviation.
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ROLE OF HLA IN IMMUNE RESPONSE 
Immune response to vaccines has been found to be 
affected by several factors, but host genetic variations 
are thought to be the main cause for variable vaccine 
responsiveness[6]. The HLA alleles, holding in one of 
the most gene-dense, but most variable regions of 
human genome, namely the major histocompatibility 
complex region[44], are essential for determining the 
specificity of an individual’s immune response[6]. 
As HLA molecules are part of the structural com-
ponent for immune recognition by T-lymphocytes, 
polymorphisms in these molecules were expected 
to modulate antibody responses to vaccination[45]. 
The HLA are coded by the major histocompatibility 
complex group of genes located on chromosome 
six in the human genome and they are essential for 
determining the specificity of an individual’s immune 
response[6]. There are three classes of HLA: HLA 
class Ⅰ, class Ⅱ and class Ⅲ. Among them, HLA class 
Ⅱ molecules have the task of presenting antigens to 
the T-lymphocytes from outside the cell. Antibody-
producing B-cells are then stimulated to produce 
specific antibodies by these antigens[46]. HLA-DQ2 
haplotype may be responsible for lack of induction 
of the Th2 response necessary for the promotion 
of the differentiation of B cells and the formation 
of memory B cells. HLA is believed to contribute 
significantly to the genetic susceptibility immune 
response variations to the vaccine[25]. Poor or non-
responsiveness to HBV vaccine has been related to 
HLA DQ2, DR3, and DR7 alleles that are also linked 
to CD[25-27]. In particular, HLA genotype DQ2, present 
in 90%-95% of individuals with CD, may have a 
fundamental part in the predisposition to a weaker 
response to recombinant HBV vaccine. Inadequate 
or scarce HBsAg-specific T-helper cells, defective 
T-helper 1 and T-helper 2 cytokine release[7,44-48], or 
reduced expression of cell-contact signal between 
activated T and B cells, such as CD40L[49] may also 
be responsible for the lack of response to HBsAg[50,51]. 
Interleukin genotype (IL10, IL12, IL18) was related 
to the development of anti-HBs antibodies in 
response to HBsAg in hemodialysis patients[52,53]. 
Chen et al[54] in 2011 found that anti-HBsAg response 
to HBV vaccination in healthy persons was closely 
related to 4 specific SNPs in the IL4, IL4RA, IL13 
and toll-like receptor (TLR2) genes and suggested 
that variation in these structures may influence the 
persistence and degree of HBV vaccine-induced 
immune response[54]. 
Other studies suggested that compliance with a 
GFD is responsible for the effect of HBV vaccine in 
patients with CD[12]. Indeed, it has been hypothesized 
that gluten intake may be the cause of failed immunity 
after vaccination. Gluten may be responsible since 
both HBsAg protein fragments and gliadin peptides 
bind to HLA-DQ2 molecules inducing proliferation of T 
lymphocytes. Defective antibody production may result 
from competition between the proteins[48].
NEW STRATEGIES FOR HEPATITIS B 
VACCINATION IN CHILDREN WITH 
CELIAC DISEASE
Inadequate effect of HBV immunization in youths 
affected by CD is a public health concern because 
those who fail to respond may become a reservoir 
of HBV infection. Thus, immune response to HBV 
vaccine needs to be studied in these patients. In 
order to prevent HBV infection in these patients and 
to achieve universal protection, new immunization 
strategies were proposed for patients with CD: the 
first is to administer booster HBV vaccine and/or 
higher doses given intramuscularly, the second is 
to use the intradermal route. The studies that have 
addressed these new immunization strategies in 
subjects with CD are summarized in Table 2[12,13,55,56]. 
Nemes et al[12] administered intramuscularly 20 µg 
of recombinant HBV vaccine as a booster to 37 non-
responder CD children on GFD, and found that 36 out 
37 (97.3%) had seroconversion 4 wk after vaccination. 
However, success with the booster vaccination after 
controlled GFD suggests that vaccination failure may 
be affected by disease activity. Few studies exist about 
HBV vaccine administered by intradermal route in 
patients with CD who do not respond to intramuscular 
recombinant vaccine. Leonardi et al[55] re-vaccinated 
20 children and adolescents with CD using a 2 µg dose 
of recombinant intradermal HBV vaccine. At 4 wk, 
they found that 15 out 20 patients (75%) showed a 
protective titer of anti-HBs. Subsequently Leonardi 
et al[56] conducted a prospective, randomized study 
involving 58 CD patients, who had been vaccinated 
in infancy, but without protective HBV antibodies 
as demonstrated by blood analysis. They randomly 
administered a 2 µg booster dose of recombinant 
HBV vaccine by the intradermal route in 30 of these 
children, and a 10 µg dose of the same vaccine by 
the intramuscular route in 28 of them. Four weeks 
after the third booster dose, 90% of patients received 
the vaccine by the intradermal route and 96.4% of 
subjects received it by the intramuscular route showed 
a protective anti HBs titer. The authors concluded 
that both routes are effective in revaccinating CD 
patients, although the intradermal route may yield a 
significantly higher proportion of higher responders.
The intradermal route may offer greater immuno-
genicity due to the straight contact between antigen 
and the immune system of the skin, also if smaller 
amounts of antigen are used[53]. Furthermore, de-
termination of a skin reaction at the place of the 
intradermal injection might be a more economic policy 
to detect anti-HBs antibodies following the booster 
vaccine[54]. Economic studies suggest that substantial 
cost-saving benefits could be achieved employing 
a fraction of the intramuscular dose through the 
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intradermal administration[57,58].
CONCLUSION 
Present evidence supports the good immunogenicity 
of vaccines in children affected by CD with the 
exception of HBV. The available literature shows that 
HBV vaccine response is lower in subjects with CD. 
Some Authors hypothesize that the lack of response to 
HBV vaccination is related to specific HLA association 
while others argue that exposure to gluten at the 
time of vaccine administration may be responsible. 
Nonetheless, non-responsiveness to HBV vaccination in 
CD subjects is a serious public health problem because 
of the wide diffusion of CD, which affects about 1% 
of the European population. Consequently, new 
vaccination strategies have been proposed in order to 
reach complete protection, including administration 
of booster shots of HBV vaccine by the intramuscular 
or the intradermal via. An evaluation of the response 
to HBV vaccine should be implemented as a routine 
assessment in youths newly diagnosed CD who were 
previously vaccinated for HBV. When unresponsiveness 
occurs, revaccination utilizing the intradermal route 
determines a potentially higher immune response 
than the intramuscular route, even employing smaller 
doses, owing to the direct delivery of antigen to the 
skin immune system. Moreover, revaccination needs 
to be done following the decline of specific antibodies, 
which commonly emerges after approximately 1 year 
of GFD. 
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